Divi’s Laboratories Limited, founded in 1990 by Dr. Murali K. Divi, is a prominent name in the global pharmaceutical industry. Based in Hyderabad, India, the company specializes in the development, manufacture, and supply of Active Pharmaceutical Ingredients (APIs) and Intermediates. Over the decades, Divi’s Laboratories has established itself as a leader in the pharmaceutical sector through a commitment to quality, innovation, and sustainability.

Divi’s Laboratories was established with the vision of creating a global pharmaceutical company dedicated to excellence in API production. Dr. Murali K. Divi’s aim was to build a company that not only meets but exceeds international standards in the production of pharmaceutical ingredients. The company went public with its [initial public offering](https://en.wikipedia.org/wiki/Initial_public_offering) (IPO) on 17 February 2003. In 2010, the company established a research centre in [Hyderabad](https://en.wikipedia.org/wiki/Hyderabad).

The company’s early years were marked by significant investments in research and development, which laid the foundation for its future success.

In the 2000s, Divi’s Laboratories began to expand its global presence by establishing advanced manufacturing facilities and increasing its product portfolio. The company invested heavily in state-of-the-art technology and infrastructure, which enabled it to offer a wide range of APIs and intermediates. This strategic investment facilitated Divi’s Laboratories in meeting the growing demands of international pharmaceutical markets.

One of the key milestones in this period was the establishment of the company’s second manufacturing unit in Hyderabad, which was designed to comply with international quality standards. This new facility allowed Divi’s Laboratories to increase its production capacity and broaden its market reach.

A cornerstone of Divi’s Laboratories’ success has been its unwavering commitment to quality and sustainability. The company adheres to rigorous quality control processes to ensure that all products meet the highest international standards. Divi’s Laboratories is also dedicated to environmental sustainability, implementing eco-friendly practices in its manufacturing processes and focusing on reducing its carbon footprint.

In 2018, Divi’s Laboratories was recognized for its environmental initiatives, receiving awards for its efforts to promote sustainable practices in the pharmaceutical industry. These initiatives include waste management programs, water conservation efforts, and the use of green technologies.

In recent years, Divi’s Laboratories has continued to innovate and expand its operations. The company has launched several new products and entered into strategic partnerships to enhance its global presence. Divi’s Laboratories is focused on expanding its R&D capabilities to develop new APIs and explore emerging pharmaceutical markets.

Looking ahead, Divi’s Laboratories aims to further strengthen its position as a global leader in the pharmaceutical industry by continuing to invest in advanced technologies and sustainable practices. The company’s future strategy includes expanding its product offerings and increasing its market share in both existing and new regions.

Divi's Laboratories custom synthesis division provides contract development and manufacturing (CDMO) services and contract research and manufacturing services (CRAMS). The company's clients include 6 of the top 10 largest multinational pharmaceutical companies.

Divi’s Laboratories has established itself as a leader in the pharmaceutical industry through a combination of innovative technologies, high-quality products, and a commitment to sustainability. With a strong foundation built on its early success and a forward-looking strategy for future growth, Divi’s Laboratories is poised to continue its leadership role in the global pharmaceutical sector.